USPTO serial 79350059
BEXIGNUS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 30, 2024
- Examiner
- BLAZICH, JOAN MICHELE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BEXIGNUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark E. Olds
Mark E. Olds Muncy, Geissler, Olds & Lowe, P.C.125 S Royal StreetAlexandria, VA 22314UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals used for the prevention and treatment of cancer, bone marrow dysfunction or suppressions, hematological malignancies, immunosystem related diseases and disorders, and diseases of chronic infections in human tissue of an individual; Medical preparations, namely, preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances for the treatment of cancer; Tumor suppressing agents; Antineoplastics being preparations and pharmaceutical products for preventing and treating cancer and other immunosystem related diseases and disorders; Anti-cancer preparations; Compounds for treating cancer, namely, pharmaceutical products for the prevention and treatment of cancer; Antibodies for medical use to prevent and treat inflammation and cancer growth and spread, bone marrow dysfunction or suppressions, hematological malignancies, and immunosystem related diseases and disorders; Biological preparations used for immune activation in the prevention and treatment of cancer, immunosystem related diseases and disorders, bone marrow dysfunction or suppressions, hematological malignancies, and chronic infections in human tissue of an individual; Adjuvants for medical purposes; Vaccine adjuvants; Anti-neoplastic preparations of chemical origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Anti-neoplastic preparations of microbial origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Antigens, namely, tumour antigens for medical diagnostic purposes and for anti-cancer preparations; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions with poor production of hematopoietic stem cells; Biotechnological preparations for medical use, namely, biological preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Immunomodulators, namely, pharmaceutical preparations for restoring and modifying the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations for the prevention of disorders of the immune system; Serotherapeutic medicines, namely, pharmaceutical preparations used for immune activation in the treatment of cancer and in the treatment of diseases of chronic infections in human tissue of an individual; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for use in hematology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 26, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 17, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 26, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 26, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 30, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 30, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 30, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 30, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 11, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 21, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 21, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 14, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 13, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 13, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 24, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 24, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 5, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 29, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 29, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 29, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 1, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 8, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 8, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 2, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 1, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 1, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 23, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 19, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 16, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |